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Cystic fibrosis is a genetic disease caused by mutations in the CFTR gene, whereas chronic obstructive pulmonary disease (COPD)
is mainly caused by environmental factors (mostly cigarette smoking) on a genetically susceptible background. Although the
etiology and pathogenesis of these diseases are different, both are associated with progressive airflow obstruction, airway
neutrophilic inflammation, and recurrent exacerbations, suggesting common mechanisms. The airway epithelium plays a crucial
role in maintaining normal airway functions. Major molecular and morphologic changes occur in the airway epithelium in both
CF and COPD, and growing evidence suggests that airway epithelial dysfunction is involved in disease initiation and
progression in both diseases. Structural and functional abnormalities in both airway and alveolar epithelium have a relevant
impact on alteration of host defences, immune/inflammatory response, and the repair process leading to progressive lung
damage and impaired lung function. In this review, we address the evidence for a critical role of dysfunctional airway epithelial
cells in chronic airway inflammation and remodelling in CF and COPD, highlighting the common mechanisms involved in the
epithelial dysfunction as well as the similarities and differences of the two diseases.
1. Introduction
Cystic fibrosis (CF) is themost common genetic disease in the
white population and results from mutations in a single gene
encoding for a 1480 residue transmembrane glycoprotein,
the cystic fibrosis transmembrane conductance regulator
(CFTR). Lung disease, characterized by chronic neutrophilic
inflammation, progressive airflow obstruction, and airway
bacterial infections, is the major cause of morbidity and
mortality in patients with CF [1, 2]. Chronic obstructive pul-
monary disease (COPD) is a major global health problem,
and it is estimated to become the third leading cause of death
worldwide by 2020; the disease is caused by both genetic and
environmental factors; among these, cigarette smoking is the
main risk factor for COPD and triggers an inflammatory
response throughout the airways, in the alveoli, and in the pul-
monary vasculature [3, 4]. The two predominant phenotypes
in COPD are emphysema and chronic bronchitis; however,
they often overlap in most patients. Although CF and COPD
are different inmany aspects, they also share key phenotypical
and pathologic features suggesting potentialmechanistic links
(Figure 1). Both diseases are associated with progressive air-
flow obstruction, chronic neutrophilic inflammation in the
airway lumen, and recurrent infectious exacerbations; disease
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exacerbations significantly contribute to morbidity and mor-
tality in both diseases and have a relevant impact on patient’s
quality of life as well as on health care expenditures [1–4].
Airway epithelial cells (AEC) are among the first sites of
contact for inhaled insults and play a crucial role in main-
taining normal airway function [5, 6]. The airway epithelium
represents the primary site of relevant molecular and histo-
logic changes in both CF and COPD, and growing evidence
in recent years has suggested that it plays a key role in disease
initiation and progression in both diseases. Structural and
functional changes in both airway and alveolar epithelium
have a relevant impact on alteration of the airway milieu,
host defences, and the repair processes that contribute to
the airflow limitation characteristic of both diseases. The
airway epithelium could therefore represent a suitable target
for novel therapeutic strategies aiming to restore barrier
integrity and defences against inhaled particles and patho-
gens. In this review, we address the evidence for a critical role
of dysfunctional airway epithelium in impaired local
defences, altered immune responses, chronic airway inflam-
mation, and remodelling in CF and COPD, highlighting the
common mechanisms involved in epithelial dysfunction as
well as the similarities and differences of the two diseases.
2. Properties of Airway Epithelium
The airway epithelium acts as a physical barrier to prevent
potential pathogens or noxious agents entering airway
mucosa and reaching the bloodstream [7]. In addition, the
airway epithelium controls ion transport to keep the airways
hydrated and, furthermore, acts as a key regulator of innate
immune responses toward invading pathogens.
2.1. Barrier Function. The crossing of one or multiple host
barriers by a pathogen is critical to initiate infection. The
airway epithelium provides a physical barrier to microbial
invasion; it consists of a monolayer of polarised epithelial
cells which maintain their integrity by apical junction com-
plexes (AJC). These consist of occluding tight junctions
(TJ), anchoring adherens junctions (AJ), desmosomes, and
GAP junctions.
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Figure 1: Similarities and differences between cystic fibrosis and COPD. Cystic fibrosis (CF) is a genetic disease caused by mutations in the
CFTR gene, while COPD is a multifactorial-acquired disease of later onset predominantly associated with cigarette smoke exposure. Although
the diseases are different in many aspects, they also share key phenotypical features. Recent evidence suggests that cigarette smoke induces an
acquired CFTR dysfunction in COPD and that both CF and COPD have corresponding molecular phenotypes of CFTR dysfunction resulting
in airway surface liquid (ASL) dehydration, mucostasis, bacterial colonization, chronic inflammation, and tissue damage. Airflow obstruction,
recurrent infective exacerbations, and a progressive decline in lung function characterize both conditions.
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TJs regulate the movement of ions, macromolecules, and
immune cells through the paracellular space; they are critical
for ion transport and act as a barrier to regulate the access of
inflammatory cells and against the entry of harmful sub-
stances such as microbial components into the airway lumen.
TJs are constructed from zona occludens proteins (ZO),
occludin, claudins, and junctional adhesion molecules
(JAMs). AJs mediate cell–cell adhesion and signalling
pathways that control cell growth, morphology, and differen-
tiation. They are located below TJs in the lateral membrane
and utilise cadherins to mediate calcium-dependent cellular
adhesion by binding a cadherin of the same type on an
adjacent cell [8]. Gap junctions are not part of AJCs and
are pathways of intercellular communication constructed
with channel proteins called connexins [9].
2.2. Mucociliary Escalator. The airway is maintained in a
constant state of hydration through the coordinated actions
of the CFTR channel and amiloride-sensitive epithelial
sodium channel (ENaC). The airway surface liquid layer
(ASL) comprises a mucus layer which functions to trap par-
ticulate matter, bacteria, and viruses, and the underlying
periciliary liquid layer (PCL), which provides hydration,
enabling effective mucociliary transport and clearance [10].
A finely tuned balance between chloride secretion by CFTR
on the one hand and sodium absorption by ENaC on the
other keeps the ASL sufficiently hydrated to permit effective
and sustained mucus clearance via the mucociliary escalator;
additional ion channels contribute to maintain ASL homeo-
stasis (reviewed in Section 3). Mucus dehydration, defective
mucociliary clearance of microbes, infection, and inflamma-
tion are the hallmarks of CF and COPD lung disease.
2.3. Pathogen Sensing. The airway epithelium senses patho-
gens using pattern recognition receptors (PRRs) including
Toll-like receptors (TLRs), RIG-I-like receptors (RLRs),
Nod-like receptors (NLRs), C-type lectin receptors (CLRs),
protease-activated receptors (PARs), and the bitter and sweet
taste receptors, amongst others. TLRs are expressed by
epithelial cells throughout the respiratory tract including
tracheal, bronchial, and alveolar type II cells and respond
rapidly to infection or tissue damage by sensing local micro-
bial and host-derived factors (Figure 2(a)). The nucleic acid-
sensing TLRs (TLR3, TLR7, and TLR9) and the RLRs, RIG-I,
and MDA-5 provide defence against viruses invading the
respiratory tract [11], by generating IL-6, CXCL8 (IL-8),
and IFN-β responses. RIG-I and MDA-5 expression is
increased in influenza A virus-infected nasal epithelium in
a process believed to resist IAV infection [12].
Various NLRs are expressed by airway epithelial cells.
NOD1 activation can reduce airway hyperresponsiveness
and decrease allergen-specific T-cell proliferation in allergen-
induced lung inflammation [13]; its expression is downregu-
latedduringpollen seasonamongpatientswithallergic rhinitis
[14]. NLRP3 mediates airway epithelial cell responses to
inhaled particulate matter, for example, PM10 [15].
A major function of epithelial CLRs is to sense fungal
species, for example, dectin-1, which recognises β-glucan
motifs in Aspergillus fumigatus and house dust mite (HDM)
[16] whereas nonfungal allergens, such as Derp1 and cock-
roach allergen, which have proteolytic properties, can elicit
allergic airway inflammation via PAR-2. Bitter and sweet
taste receptors (T2R and T1R, resp.) are G-protein-coupled
receptors expressed in respiratory epithelia (reviewed in
[17]) that are activated by quorum-sensing molecules such
as homoserine lactones from Pseudomonas aeruginosa or
sugars. Their activation can enhance mucociliary clearance
[18]. In addition, new roles are emerging for other receptors
expressed by airway epithelium such as fractalkine receptor
CX3CR1 [19] and the short-chain fatty acid receptor
GPR41 [20].
In addition to membrane-bound PRRs, in the lung, solu-
ble forms also exist that include mannose-binding lectin
(MBL) and surfactant proteins A and D. Ligands for MBL
include high mannose and N-acetylglucosamine oligosaccha-
rides that trigger the activation of the classical complement
pathway [21]. Surfactant proteins (SP) B and C lower alveolar
surface tension whereas SP-A and SP-D bind to macrophages
and stimulate their chemotaxis [22] or Gram-negative bacte-
ria and inhibit T-cell proliferation [23], respectively.
2.4. Innate Immunity. The airway epithelium plays a key role
in the lung’s innate immune responses. Together with the
complement system, the antiproteases, antimicrobial pep-
tides, and cytokines expressed by airway epithelial cells or
present within the airway lumen represent major factors that
function to rid the lungs of infectious or invading microbes
and cope with toxic intrapulmonary insults due to pathogens
or environmental pollutants.
The complement system opsonizes pathogens and gener-
ates chemotactic peptides and the membrane attack complex
[24]. Alpha-1 antitrypsin (AAT), secretory leukoprotease
inhibitor (SLPI) and elafin are the most abundant serine anti-
proteases in the lung. Each has important beneficial effects
within the lung and their dysregulated activity can adversely
impact on the inflammatory process (Figure 2(b)) [25–30].
Antimicrobial peptides form part of the lung’s innate
immune defences, and inactivation of these peptides has been
implicated in airway infections (Figure 2(b)). Lactoferrin is a
monomeric iron-binding glycoprotein (76–80 kDa) present
in the secondary granules of neutrophils [31]. It plays a
microbiostatic role in mucosal fluids [32] and also has antivi-
ral, antifungal, and anticancer activities and can act as an
immunomodulator. The primary functions of LL-37 are to
eliminate pathogens, inhibit biofilm, and enhance the
immune responses [33]. Human beta-defensins are small
(4–6 kDa) cationic peptides. Twenty-six human DEFB genes
have been identified but only HBD1–4 are secreted by the
respiratory tract and play a role in airway mucosal defense.
HBDs possess antibacterial [34], antiviral [35], and antifun-
gal properties [36]. HBD-2 and HBD-3 also have immuno-
modulatory properties [37].
3. Mucus Production/ASL Regulation in CF
and COPD
As previously described, the airway epithelium is covered by
the ASL that comprises a mucus layer and the underlying
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PCL. Airway mucus is responsible for hydration of the epi-
thelium and acts as an essential protective component of
the innate defense system of the airways [38, 39]: inhaled
microorganisms, noxious agents, and particles get entrapped
in mucus and eliminated by mucociliary clearance (MCC)
and/or cough, thus protecting the lung from airway infection
and inflammation. The two main secreted airway mucins are
MUC5AC and MUC5B [38, 40]; the latter but not MUC5AC
seems to be required for airway defence against bacteria [41].
Properly hydrated mucus is a critical component of airway
homeostasis; failure to maintain adequate mucus hydration,
mucus hypersecretion, and altered mucus properties lead to
impairment of mucociliary clearance and are prominent fea-
tures of chronic airway diseases such as CF and COPD, con-
tributing to airway obstruction in these diseases. Ion
channels that regulate Na+ and Cl− transport are required
for the proper hydration and composition of ASL. CFTR is
the primary apical ion channel involved in Cl− transport in
the lung epithelium; in addition, it is also implicated in the
regulation of ENaC that is rate limiting for Na+ and fluid
absorption from the airway surface. Additional ion channels
in the airway epithelium play a role in maintaining ASL
homeostasis, including the solute carrier 26A (SLC26A) fam-
ily of anion exchangers and calcium-activated chloride chan-
nels [42, 43]. Alterations in ASL composition and disruption
of this tightly regulated airway milieu have been linked to the
pathogenesis of CF lung disease and COPD. In CF, the
defect/dysfunction of the CFTR protein causes a defect in
chloride and bicarbonate transport into the airway lumen
that results in dehydration and acidification of ASL, produc-
tion of viscous, acidic, and altered secretions, with impair-
ment of MCC; this in turn induces airway obstruction,
favouring chronic bacterial infection and inflammation
(Figure 3). Recent studies showed that the ASL volume deple-
tion causes a collapse of cilia and impairs mucus transport,
further supporting the concept that ASL dehydration is a cru-
cial mechanism in CF lung disease [42]. The role of airway
surface dehydration as a disease-initiating mechanism is also
supported by studies in βENaC transgenic mice and in
SCL26A9 mice [44–48]. Recent biophysical studies provided
novel insight on the effects of airway surface dehydration,
showing that this leads to an increase of the concentration
of secreted mucins and consequently of the osmotic pressure
of the mucus layer; when the latter increases above a critical
threshold, the PCL and the cilia get compressed leading to
stasis and adhesion of mucus on the airway surface [49]. This
critical mucus hyperconcentration may be induced not only
by the CFTR ion transport defect but also by airway inflam-
mation; thus, it may play an important role in the pathogen-
esis of chronic inflammatory diseases such as COPD [50].
In addition to airway surface dehydration, the impaired
bicarbonate secretion mediated by CFTR dysfunction results
in altered mucus structure, increased viscosity and abnormal
mucus secretion; therefore, it may contribute to mucus plug-
ging and the impairment of MCC in CF lung disease beyond
that caused by airway dehydration alone. Several recent stud-
ies support the key role of bicarbonate secretion in regulating
local pH and the airway milieu and in maintaining normal
mucus properties: bicarbonate, in fact, drives ionic content
and fluids on epithelial surfaces and allows mucins to unfold,
and its depletion has been shown to result in dense mucus
and increased ASL viscosity thus impairing mucociliary
transport [51–53]. Altered ASL viscosity would be a primary
CF defect that might contribute, at least in part, to the path-
ogenesis of CF lung disease. Subsequently, infection, inflam-
mation, and airway remodelling, with their consequences,
may further modify ASL viscosity and further enhance the
defect of mucociliary transport. Loss of CFTR-mediated
bicarbonate secretion has also been shown to inhibit the
activity of antimicrobial peptides present in ASL [53]. Thus,
dysfunction of CFTR and the subsequent lack of bicarbonate
and chloride secretion create an abnormal airway milieu,
with impaired innate host defences that favours chronic air-
way infection and inflammation leading to progressive lung
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Figure 2: Airway innate immunity. (a) The major pattern recognition receptor (PRR) is the Toll-like receptor (TLR) family which interact
with microbial-derived factors or pathogen-associated molecular patterns (PAMPs) such as LPS from P. aeruginosa. LPS-induced
activation of TLR induces an IL-8 response via a NF-κB pathway. (b) Important antiproteases and antimicrobial proteins in the lung
include AAT, SLPI, elafin, the cathelicidin LL-37, lactoferrin, and the human beta defensins (HBDs); these can be cleaved and inactivated
by neutrophil elastase in the CF lung. CBM: capillary basement membrane.
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injury and ultimately to respiratory failure (Figure 3).
Furthermore, recently, it has been shown that the loss of
CFTR leaves H+ secretion by the nongastric H+/K+ adenosine
triphosphatase (ATP12A) unchecked, which further
decreases the ASL pH further impairing airway innate host
defences [53].
Cigarette smoking is the major risk factor for COPD, a
disease that shares some phenotypical features with CF, such
as impaired mucociliary clearance, chronic airway inflamma-
tion, progressive airflow obstruction, and recurrent bacterial
exacerbations. In particular, COPD patients with the chronic
bronchitis phenotype exhibit pathologic and clinical features
similar to CF, including goblet cell hyperplasia, mucin hyper-
expression, andmucus accumulation and hypersecretion that
contribute to bacterial infection and subsequent inflamma-
tory responses and have been associated with lung function
decline in COPD patients (Figure 1).
Increasing evidence shows that cigarette smoking induces
an acquired CFTR dysfunction in patients with normal
CFTR gene. Welsh firstly reported that cigarette smoke
decreases chloride secretion in the airway epithelium [54].
Several subsequent studies then showed that sustained expo-
sure to cigarette smoke and cigarette smoke extract (CSE)
was able to reduce CFTR expression and function in vivo in
smokers and in COPD patients and in airway epithelial cells
in vitro [55–58]. Several independent mechanisms have been
proposed to account for these effects of smoke, including
aberrant transcript expression, direct effects of smoke metab-
olites on CFTR function, and accelerated internalization of
CFTR Cl− channels from the apical plasma membrane
(Figure 4) [55, 56, 58–61]. Smoke-induced CFTR dysfunc-
tion results in ASL dehydration, and it was shown that ASL
height decreased permanently after chronic smoke exposure
due to changes in active ion transport, indicating an effect
of smoke on ASL homeostasis. It has also been shown that
CSE is capable of inducing a delayed mucociliary transport
in vitro and a marked increase of mucus expression both
in vitro and in vivo. CSE has also been shown to be capable
of inducing MUC5AC expression and mucus hyperproduc-
tion in AEC, an effect that seems to be mediated through
ROS-dependent autophagy [62–64]. Together with mucin
hypersecretion, smoke-induced CFTR dysfunction will
aggravate mucus hyperconcentration and plugging in COPD
airways (Figure 4) [42, 65–68]. Tobacco smoke components
such as acrolein and acetaldehyde have been shown to impair
mucociliary clearance [69]; furthermore, acrolein and
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Figure 3: Pathophysiology of airway disease in cystic fibrosis. In cystic fibrosis, loss of normal CFTR function and overactivity of ENaC result
in acidification (loss of HCO3− secretion) and dehydration of the airway surface liquid layer (ASL) disrupting the normal mucociliary
escalator. This results in an increase in ASL viscosity, mucus plugging, bacterial colonization, and neutrophil-dominated inflammation. An
overabundance of bacterial and neutrophil derived proteases degrades important antiproteases and antimicrobial peptides in the CF
airways further compounding an already-overwhelmed impaired innate immune system.
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cadmium inhibit CFTR function in vitro and can reach
detectable levels in humans as well (Figure 4) [70, 71].
In ciliated cells from nasal brushing of smoke-exposed
subjects and moderate/severe COPD patients, ciliary beat
frequency was significantly reduced compared to control
subjects [72, 73]. Furthermore, CS exposure has been shown
to affect ciliogenesis and to cause ciliary shortening [74],
effects that further contribute to the impairment of MCC.
Reduced MCC leads to accumulation and adhesion of
mucus in the airways, favouring retention of irritants and
noxious agents contained in cigarette smoke. This in turn
triggers exaggerated inflammatory/immune responses, with
recruitment of neutrophils and macrophages and excess of
protease release that promotes the formation of emphysema
in the lungs of smokers with COPD [60, 75]. Recent studies
shows that CFTR protein expression correlates inversely with
emphysema severity in lungs of COPD patients, suggesting
that impaired CFTR function may also be implicated in
emphysema formation in humans [76]. A role of CFTR
dysfunction in the pathogenesis of emphysema is further
supported by studies in βENaC transgenic mice demonstrat-
ing that CF-like airway surface dehydration does cause not
only chronic mucus obstruction and airway inflammation
but also emphysematous changes in these mice [44, 46, 77].
Interestingly, we demonstrated that genetic deletion and
pharmacologic inhibition of PI3Kγ decreases both neutro-
philic airway inflammation and structural lung damage in
βENaC transgenic mice [78].
As previously discussed, defective CFTR also decrease
bicarbonate secretion, that is, crucial in pH ASL regulation
and in maintaining normal mucus properties. Tobacco
smoke exposure decreases bicarbonate secretion presumably
resulting in acidification of ASL and increased ASL viscosity
(Figure 4) [42, 79, 80].
A marked decrease of CFTR function has been reported
in the upper and lower airways of smokers and patients with
COPD; interestingly, in COPD patients, significant correla-
tions have been shown between clinical manifestations such
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Figure 4: Effects of cigarette smoke on CFTR and pathophysiology of airway disease in COPD. Cigarette smoke components (e.g., acrolein
and cadmium) can decrease expression and function of the CFTR protein by decreasing CFTR mRNA and protein levels, accelerated CFTR
internalization, and decreased channel opening probability (Po). Increased levels of neutrophil elastase in COPD may worsen CFTR
dysfunction by degrading CFTR and upregulating ENaC expression. Loss of CFTR function results in ASL dehydration and acidification,
mucus hypersecretion, and mucus plugging leading to reduced mucociliary clearance, chronic inflammation, impaired innate immunity,
and infection.
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as dyspnea and symptoms of chronic bronchitis and the
levels of CFTR suppression in their lower airways [56]. The
marked oxidant burden and neutrophilic inflammation
associated with COPD and particularly with advanced dis-
ease further aggravate the effects of CFTR dysfunction in
COPD airways. Studies using cell lines expressing wild-
type CFTR have shown that a prolonged exposure to oxi-
dant stress with either t-butylhydroquinone or cigarette
smoke extract was capable of inhibiting CFTR function,
protein levels, and gene expression [55, 81, 82]. Further-
more, it has been reported that CS-induced CFTR dys-
function and the associated inflammatory/oxidative stress
cause an impairment of autophagy that also contributes
to the development of emphysema [56, 82, 83].
All these data support the concept that CFTR dysfunc-
tion caused by cigarette smoke may contribute to the patho-
physiology of COPD and may represent a potential target for
the development of novel therapeutic approaches.
4. Innate Immune Response in CF and
COPD Epithelium
The airway epithelium contributes to host defence by a
variety of mechanisms including its barrier function and
mucociliary clearance, as well as by the production of antimi-
crobial peptides and proteins and a range of cytokines,
chemokines, and growth factors that mediate leukocyte
recruitment, modulation of innate and adaptive immunity,
and tissue repair and remodelling [84–86]. Through these
mechanisms, the airway epithelium contributes directly to
host defence and augments the immune response via the
recruitment of inflammatory/immune cells and the interac-
tion with other structural cells in the airway wall.
4.1. Innate Immune Responses in CF Epithelium. A vicious
cycle of infection followed by intense neutrophil-dominated
inflammation, ineffective clearance of infection, and irrevers-
ible airway destruction is characteristic of CF. Airway inflam-
mation is ultimately driven by a dysfunctional epithelium
due to an impairment in innate host defence systems,
secondary to mutations of CFTR [87–90]. Defective bicar-
bonate secretion due to CFTR dysfunction reduces ASL pH,
impairing the activity of antimicrobial peptides and mucus
properties. Despite the ineffectiveness of the CF airway sur-
face to remove mucus, goblet cells are likely to continue
secreting mucins [91] leading to plugging. Specific defects
in many aspects of the lung’s innate immune repertoire are
evident in CF.
The CF airway is a TLR agonist-rich environment, and
chronic inflammation in CF may for the most part be due
to activation of TLRs [92]. Although TLR hyperrespon-
siveness is largely accepted to contribute to CF lung dis-
ease, hyporesponsiveness to TLRs can also negatively
impact on pulmonary inflammation. During high circulat-
ing oestrogen (E2) states in the female CF airways, a TLR
hyporesponsiveness, manifested by reduced IL-8 release,
occurs in response to a range of bacterial agonists [93].
A hyporesponsive state may be problematic, leading to
ineffective clearing of microorganisms.
NOD1 (or CARD4) and NOD2 (or CARD 15) detect
peptidoglycan of Gram-positive or Gram-negative bacteria,
and their activation causes induction of proinflammatory
NF-κB-dependent cytokines [94]. IL-17 has been shown to
augment expression of NOD1, NOD2, and TLR4. By upreg-
ulating these PRRs, IL-17 primes the airway to increase its
inflammatory response (IL-8) to bacterial ligands. Interest-
ingly, pretreatment of CFTRΔF508 cells with IL-17 resulted
in a 10-fold increase in IL-8 synthesis following treatment
with a NOD1 agonist, highlighting the importance of
NOD1 as contributor to aberrant inflammatory responses
in the CF lung [95].
Polymorphisms in the mannose-binding lectin 2 (MBL2)
promoter can affect MBL serum levels. Relative deficiency of
MBL appears to accelerate the age-related decline in lung
function in CF patients as MBL-deficient patients older than
15 years of age displayed poorer lung function compared
with those younger than 15 years of age [96].
Likewise, relative reduction in SP-A and SP-D has been
observed in patients with CF [97] and levels inversely corre-
late with inflammation and bacterial burden [98]. The cause
may be related to the ability of P. aeruginosa elastase and pro-
tease IV to degrade SP-A and SP-D in the CF lung [99, 100].
Furthermore, CFTR-dependent alterations in complement-
mediated interactions between P. aeruginosa and monocytes
may contribute to enhanced susceptibility to infection in
patients with CF [101].
An inherent proinflammatory state exists in the CF air-
ways and may precede bacterial colonization. Overproduc-
tion of the neutrophil chemokine IL-8 by CF airway
epithelial cells may be a consequence of both intrinsic CFTR
dysfunction [102] and infection [103]. Elevated concentra-
tions of proinflammatory cytokines including TNF-α, IL-1,
and IL-8 have been found in children with CF [104]. TNF-
α concentrations in sputum are not significantly correlated
with clinical status but do show a strong correlation with
sputum IL-8 levels [105].
Interleukin 17 (IL-17-A/F) is a proinflammatory cytokine
with roles in the immunopathogenesis of CF and COPD.
Elevated IL-17A mRNA and protein in CF sputum implicate
this cytokine in the persistent neutrophilic infiltration in CF
lung disease [106]. IL-17 positively regulates the production
of proneutrophilic mediators from CF epithelial cells by
increasing IL-8 and IL-6 [107]. IL-17A is significantly higher
in BALF of symptomatic patients as compared with clinically
asymptomatic patients with CF, and its increased concentra-
tions precede infection with microbes such as P. aeruginosa
and thus have clinical relevance [108].
Antiproteases within the CF lung are susceptible to cleav-
age and inactivation by host proteases (Figure 2(b)). SLPI is
susceptible to cleavage by cathepsins B, L, and S [109] and
elafin by NE in lungs of patients colonized with P. aeruginosa
[110]. Although levels of AAT rise in acute inflammation, in
the CF lung, the inhibitory activity of AAT is overwhelmed
by an excess of NE.
While lactoferrin has been reported to be present at
higher concentrations in the CF lung compared with nor-
mal lungs [111], its activity may be suboptimal secondary
to cleavage by Pseudomonas elastase and NE [112].
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Cleavage of lactoferrin by cathepsins B, L, and S also
results in loss of its microbicidal and antibiofilm activity,
and in the CF lung, this may potentiate the biofilm form-
ing ability of P. aeruginosa [113].
The effectiveness of LL-37 may be hampered in the CF
lung through complexing with polymers including GAGs
or DNA released from the breakdown of neutrophils and
other cells [114, 115].
Finally, variant alleles (single-nucleotide polymorphisms)
in the DEFB1 gene encoding HBD-1 may contribute to the
colonization of P. aeruginosa in CF [116]. Beyond that, cystei-
nyl cathepsins which are present at higher than normal levels
in the CF lung cleave and inactivate HBD2 and HBD3 [117].
4.2. Innate Immune Responses in COPD Epithelium. An
increasing number of studies demonstrate that epithelial
defence functions are altered or decreased in chronic air-
way diseases including COPD and that, as described in
CF, defects in the innate immune system play a relevant
role also in the pathogenesis and pathophysiology of
COPD [5, 42, 118–123]. Cigarette smoke induces relevant
alterations in the airway epithelial architecture and impairs
epithelial barrier function by increasing the permeability of
the airway epithelium, decreasing ciliary function, and reduc-
ing mucociliary clearance. This epithelial barrier dysfunction
in turn can increase the entry of pathogens and noxious par-
ticles into the airway mucosa, further impairing the barrier
function and host defences [4, 5, 39, 124, 125–130]. Cigarette
smoke induces mucous cell hyperplasia and mucus hyperse-
cretion contributing to airway obstruction; in the small air-
ways, smoking-induced goblet cell hyperplasia is associated
with loss of club cells, responsible for the production of secre-
toglobin, surfactant protein, and other defense factors
[131]. A reduced expression of polymeric immunoglobulin
receptor/secretory component (pIgR/SC) has also been
reported in the COPD epithelium that impairs the transe-
pithelial transport of secretory IgA and correlates with the
severity of airflow obstruction [132]. Cigarette smoke may
affect epithelial cell functions through a variety of mecha-
nisms, including direct oxidant activity, TLR signalling, ER
stress induction, and activation of the integrated stress
response [133, 134]. In addition to impairing barrier func-
tion, cigarette smoke exposure increases the release of
inflammatory mediators by AEC, whereas it decreases the
expression and activity of ASL antimicrobial peptides
(AMP). This defect, caused by smoking-induced CFTR dys-
function, is common to CF airways and contributes to the
increased susceptibility to respiratory infections shared by
both diseases. The antimicrobial activity of AMPs may also
be affected by other conditions occurring in both CF and
COPD airways such as AMP degradation by microbial and
host proteases and AMP inhibition by microbial polysaccha-
rides, F-actin, and DNA from dying cells. Cigarette smoke
also inhibits the molecular pathways involved in interferon
production in response to viral infections [135]. Whereas
the expression and activity of epithelial AMP are impaired
in COPD, the levels of neutrophil-derived peptides and LL-
37 are increased as a consequence of the marked neutrophilic
inflammation in this disease and further increase during
disease exacerbations [136–145]. Likewise, increased levels
of lysozyme and lactoferrin have been reported in BALF of
patients with COPD [121, 146], whereas SLPI levels were
reported to be increased in stable patients, but decreased dur-
ing disease exacerbations [144, 147, 148]. However, some
inconsistent findings concerning sputum AMP levels in
COPD patients have been reported in previous studies
[136–139, 149] that may be due to the small sample sizes of
these studies and the different clinical conditions and disease
stage of patients.
Exposure to cigarette smoke also leads to activation of
several PRRs, either directly by components of smoke or
indirectly by causing injury to epithelial cells [84, 121, 134,
150, 151]. As in CF, also in COPD, TLR4 has been suggested
to play a key role in the inflammatory/immune response:
TLR4-defective mice show attenuated lung inflammation
after challenge with cigarette smoke [152–154]. Elevated
levels of damage-associated molecular patterns (DAMPs),
such as high-mobility group box 1 (HMGB1) [155], uric acid,
and extracellular ATP [156], have been observed in the BALF
of patients with COPD compared with smokers without
COPD. Extracellular ATP has been shown to activate the
NLRP3 inflammasome, regulating the expression of interleu-
kin-1β and IL-18, [153] particularly during disease exacerba-
tions [157, 158]. In IL-1R knock-out mice, pulmonary
inflammation induced by acute exposure to cigarette smoke
was attenuated and these mice were protected against emphy-
sema after chronic smoke exposure [159].
Activation of AEC by cigarette smoke or pathogens also
triggers an inflammatory response, with the release of cyto-
kines and chemokines such as TNF-α, IL-1, IL-6, GM-CSF,
and IL-8 acting on inflammatory/immune cells as well as
on resident cells [5, 84, 85, 119, 121, 134, 150, 152, 158].
Similar to what occurs in CF airways, activated AEC from
COPD patients release more IL-8 than cells from smoking
control subjects [160] and display a proinflammatory pheno-
type in culture [161], although the molecular mechanisms
are different in CF and COPD. Levels of IL-17 and other
Th17 cytokines are also increased in sputum and airways of
patients with COPD as reported in CF, further enhancing
neutrophil recruitment. [162, 163]. Whereas physiologically
the inflammatory process induces protective immune
responses, in patients with COPD and CF, chronic airway
inflammation amplifies the tissue damage and further
impairs local immune defences, thus contributing to suscep-
tibility to recurrent infections. Neutrophils and alveolar
macrophages are increased and activated in COPD, as well
as in the CF lung, and contribute to the oxidant burden and
the protease/antiprotease imbalance that drive the develop-
ment of emphysematous changes in both diseases. Further-
more, neutrophils from COPD patients show altered
chemotactic responses [164] that impair their defence func-
tion whereas macrophages show reduced phagocytic ability
[165–167] and impaired innate responses to respiratory
pathogens. These alterations facilitate the chronic coloniza-
tion of the airways and infectious exacerbations [168]. An
increased number and activation of dendritic cells in the lung
of patients with COPD have also been reported in some stud-
ies that seem to correlate with disease severity [169–171],
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whereas other studies have found decreased numbers of these
cells and an impaired maturation status [172–175]. Recent
studies suggest that innate lymphoid cells (ILC), with impor-
tant roles in immune homeostasis and lung immunity, may
play a role in COPD [176–178]. In mice exposed to cigarette
smoke, a strong type 1 response to influenza virus was
observed that was associated with a transdifferentiation of
ILC2 into ILC1 cells, induced by IL-12 and IL-18 [178]; in
patients with COPD, an increase of ILC1 and a decrease of
ILC2 cells was reported in lung tissue [178, 179]. Finally,
recently, it has also been reported that pulmonary natural
cytotoxicity receptor- (NCR-) ILC3 cells tend to accumulate
into the lungs of COPD patients [177]; these cells produce
IL-17A and IL-22 and might contribute to driving neutro-
philic inflammation in the COPD airways. Interestingly,
these cytokines are also crucial in the formation of lymphoid
follicles [180, 181], the numbers of which are increased
around the small airways and in the lung parenchyma
[182–184] in severe COPD as well as in peribronchial, paren-
chymal, and perivascular areas in the lung of CF patients with
advanced lung disease [185]. The peribronchial localization
of tertiary lymphoid organs and the epithelial expression of
IL17A and chemokines involved in their development
suggest a role for airway epithelium in lymphoid neogenesis
in these diseases. However, differently from COPD, a shift
from B cell to T-cell predominance has been observed in
CF lymphoid follicles, suggesting that the cellular adaptive
immune response is specifically affected in CF [185].
Recently, Frija-Masson and colleagues [186] showed that
peribronchial lymphoid neogenesis was induced in the lungs
of mice upon persistent bacterial infection, suggesting that
chronic bacterial infection contributes to the lymphoid neo-
genesis observed in both COPD and CF.
A growing body of evidence now suggests that dys-
function of epithelial innate immune responses and the con-
sequent chronic airway inflammation can drive the initiation,
exacerbation, and progression of chronic inflammatory
disease such as COPD and CF. In this context, therapeutic
targeting of dysfunctional immune responses could be an
interesting strategy in the treatment of these diseases.
5. Comparison of Epithelial Remodelling in CF
and COPD
Efficient epithelial regeneration following injury is crucial in
tissue homeostasis and prevention of disease. Exposure to
repeated noxious/inflammatory stimuli as well as airway
epithelial dysfunction affects epithelial regeneration and
repair pathways and the ability of epithelial cells to restore
barrier functions; this leads to aberrant remodelling and
structural damage that further impair epithelial functions
and generate a vicious cycle favouring aggressions by
potential exogenous insults.
Both CF and COPD are characterized by dysfunctional
airway epithelial repair and remodelling that impair
lung architecture and contribute to disease pathogenesis
and progression.
In CF, progressive remodelling of the airways ultimately
results in structural damage with development of
bronchiectasis, emphysema, and impaired lung function.
Differently from COPD, structural changes of the airway
and alveolar wall in CF appear early in life. There is still
debate about the sequence of events leading to remodelling
and structural alterations in CF and their relationship to
infection and inflammation; in particular, it is still debated
whether structural changes are related to and initiated by
infection/inflammation or are a result of CFTR dysfunction
independent of infection and inflammation [87–90, 102–
104]. Hyperplasia of goblet cells and basal cells [187–190],
squamous metaplasia [187, 190, 191], increased epithelial
height [187, 192], cell shedding [187–190, 193], with loss
of ciliated epithelial cells, and a disorganization of tight
junctions and compound cilia [192, 194–196] have been
reported in the context of epithelial remodelling in CF
airways; extensive structural changes of the small airway
epithelia have also been observed, including epithelial
shedding and altered barrier integrity [197]. Conflicting
results have been reported concerning epithelial and retic-
ular basement membrane (RBM) in adult patients that was
found thickened in some studies [189, 198, 199], but signifi-
cantly thinner than normal in other studies [200]. Interest-
ingly, many of these structural changes are similar to those
observed in COPD, although the molecular mechanisms
initiating these changes are different.
Whereas until recently, little was known about the fre-
quency of occurrence and the clinical relevance of emphyse-
matous changes in CF lung disease, recent studies show that,
with the remarkable increase of patient survival, emphysema
is now a more prominent disease component in CF. Using
quantitative CT measurements, Wielpütz and colleagues
[201] showed that early onset and progressive emphysema
is a characteristic feature of CF lung disease; emphysema is
observed in early adolescence, increases in adult CF patients,
correlates with lung function, and contributes to disease
severity. Mets and colleagues [202] pathologically and
radiologically confirmed that emphysema is common in
advanced CF lung disease, is related to age, and in some cases
approaches the changes observed in explanted lungs of
COPD patients. Thus, emphysema might become an
increasingly important disease component in the aging CF
population. Several mechanisms mainly related to CFTR
dysfunction may induce emphysema formation in CF
patients; among these, chronic inflammation with protease/
antiprotease imbalance and extracellular matrix proteolysis,
altered ceramide metabolism, alveolar apoptosis, and defec-
tive autophagy [63, 76, 203]. Most of these mechanisms are
common to those involved in the pathogenesis of smoke-
induced emphysema.
Some studies have reported that CFTR plays an impor-
tant role in regulating the early events of epithelial cell migra-
tion [188, 198, 200] and that CF airway epithelial cells exhibit
slower migration and wound repair than non-CF cells
[188, 198, 204]. The findings that the pharmacological res-
cue of CFTR function in CF cells significantly improved
wound healing and that inhibition of CFTR expression
or activity decreased proliferation and migration of non-
CF airway epithelial cells [188, 198] further support the
role of CFTR in modulating airway epithelial cell
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migration and the concept of a dysfunctional airway epi-
thelium in CF. Data obtained on tissues from CF fetuses
(taken at autopsy) or in a humanized nude mouse xeno-
graft model and in CF mice suggest that the epithelial
remodelling starts to occur prenatally and in the absence
of infection [205–207]. A recent in vitro study, using CF
human airway epithelial cell cultures, confirmed and
extended these findings, showing that CF epithelium
regeneration, even in the absence of exogenous infection/
inflammation, was abnormal and associated with basal cell
hyperplasia and with delayed ciliated cell differentiation.
The findings of this study demonstrate that the abnormal
remodelling in CF epithelium was partly induced by the
intrinsic hyperinflammatory phenotype of CF cells [208].
Interestingly, in this study, an increase in CF epithelium
height was observed in the context of epithelium remodel-
ling. An increased epithelium height was previously
reported in vivo in CF lungs as compared with lungs from
COPD patients [192] and in these latter patients as com-
pared with non-COPD subjects at both the nasal and
bronchial levels [209]. Similarly, basal cell hyperplasia, a
finding associated with increased epithelium height, was
also reported in vivo in CF [187, 189] and COPD lungs
[210]. It has been already emphasized that chronic inflam-
mation is a hallmark of CF; inflammation begins early in
the disease even in the apparent absence of infection, and it
has been postulated that it may be dysregulated in the CF
lung as a consequence of defective CFTR [87–90, 102–104,
211, 212]. Interestingly, stimulation of non-CF airway epi-
thelial cells with proinflammatory cytokines mimicked the
abnormal remodelling observed in CF epithelial cells and
induced an increase of epithelium height and basal cell num-
bers comparable to those observed in CF cultures [208].
Overall, the findings of the previous studies suggest that
exogenous infection and inflammation are not the exclusive
factors affecting airway epithelium remodelling in CF and
that the intrinsic dysfunction of CF airway epithelial cells
plays an important role in this process and in the alterations
of epithelial regeneration following injury. A growing num-
ber of in vitro and in vivo studies support the notion that
chronic neutrophilic inflammation is a key factor in struc-
tural lung damage and lung function decline in CF through
the release of damaging neutrophil products such as NE
and reactive oxidant species [211, 212]. Airway inflammation
is further augmented after onset of chronic airway infection.
A vicious cycle of neutrophilic inflammation, noxious medi-
ator release, and overwhelmed defences occurs within the
airways that further exacerbates epithelial injury and
remodelling, leading to disease progression and irreversible
lung damage. The chronic neutrophilic inflammation,
heightened during acute exacerbations of the disease, is a
common process in CF and COPD and may be involved
in the common abnormalities observed in vivo in remo-
delled airway epithelium, as well as in the destructive
alterations of airway and alveolar walls.
There is evidence of degradation of structural compo-
nents of the extracellular matrix (ECM) such as elastin, colla-
gen, and glycosaminoglycans in the CF lung; these alterations
are associated with the marked and early protease/
antiprotease imbalance, with the release of high quantities
of matrix metalloproteases (MMP), NE, and other proteases
that contribute to the tissue damage and development of
bronchiectasis and emphysema [213–216]. There is increas-
ing evidence that the high levels of free NE activity observed
in sputum and BALF from CF patients not only are able to
cleave a number of ECM proteins but have also other direct
and indirect deleterious effects on the epithelial repair
process: in fact, they significantly impact the adhesion, prolif-
eration, and wound repair of primary AEC [217]. There is
also considerable in vivo evidence of an imbalance of MMP
and their inhibitors (tissue inhibitors of MMP, TIMPs) in
the CF airways with prevalence and activation of MMP
[214, 218–221]. Activation of MMP-7 has been shown to
inactivate AAT, thus further augmenting the effect of free
NE activity [221], whereas the release and activation of
MMP12 is involved in alveolar wall destruction [63]. A
recent proteomic study of CF AEC showed significantly
increased secretion of ECM proteins fibronectin, laminin,
perlecan, and galectin-3 [222], whereas the CFTR defect
was associated with a decreased integrin β1 signaling and a
reduced wound repair [223]. These studies further support
a role of mutant CFTR protein in the abnormal migration
and reparative properties of the CF epithelium. Fibrotic
changes associated with small airway narrowing have also
been described, in particular in end-stage CF [224–226]. A
recent study, using micro CT and histology documented
dilatation and obstruction of distal airways and a severe
reduction in the number of functional terminal bronchioles
in end-stage CF lungs, confirming that, similar to COPD,
obstruction and remodelling of peripheral airways are a
prominent feature in CF lung disease [226].
Similar to CF, the airway epithelium represents a pri-
mary site of relevant molecular and morphologic changes
in COPD; structural modifications of the epithelium in
COPD resemble that observed in CF and include basal cell
hyperplasia, squamous metaplasia, goblet cell hyperplasia,
decreased integrity of the apical junctional barrier, and
epithelial shedding [132, 222, 227]. Moreover, a reduction
of cilia length and ciliary beating have been observed in
COPD and upon cigarette smoke exposure [72, 127];
altered function and/or number of ciliated and goblet cells
impair mucociliary clearance, contributing to the develop-
ment of airway obstruction similar to what occurs in CF.
Although pathologic changes in COPD lungs involve both
the airways and parenchyma, studies by Hogg and col-
leagues clearly showed that smoking-induced changes in
the small airways are crucial in the development of airway
obstruction in COPD and precede destruction of the alve-
olar structure [228], similar to what was observed in CF.
Interestingly, recently, it has been reported that smoking
is able to induce a distal-to-proximal reprogramming of
the small airway epithelium in COPD lungs, with a shift
toward the proximal airway epithelial phenotype. These
changes represent a novel feature of small airway pathol-
ogy in COPD and seem to be mediated by exaggerated
epidermal growth factor/epidermal growth factor receptor
signaling in small airway epithelium basal cells [229]. An
increased expression of epithelial growth factor receptors
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has been described in AEC of COPD patients, which
might contribute to squamous metaplasia and an increased
risk of bronchial carcinoma [230].
Normal differentiation of epithelial cells in COPD is
altered both in terms of cellular functions and of the polarity
of the epithelial cells, notably through epithelial to mesen-
chymal transition (EMT). This leads to dysfunctional physi-
cal, chemical, and immune barrier functions; whilst aberrant
repair and remodelling of the COPD epithelium further
impair epithelial functions. Cigarette smoke increases epithe-
lial permeability by disassembly of tight junction proteins via
the epidermal growth factor receptor pathway [124]. This
may favour viral, fungal, and bacterial translocation through
the epithelium.
As described for CF AEC, Perotin et al. recently showed
that wound repair is delayed in primary cultures of severe
and very severe COPD [231]. The epithelial cells undergoing
EMT lose their epithelial phenotype, become able to migrate
along and through the basement membrane, and presumably
participate to peribronchial fibrosis [232]. EMT is reported
both in upper airways (in chronic sinusitis) [233, 234] and
in small and large lower airways in COPD [235] and is
induced by cigarette smoke and by TGF-β [236, 237].
Cigarette smoke also promotes Wnt signaling: Heijink and
colleagues reported that cigarette smoke increases Wnt-5B
expression in COPD AEC cultures and favours a mesenchy-
mal phenotype through a mechanism involving TGF-β/
Smad-3 [238]. More recently, Baarsma and colleagues
showed an enhanced expression of noncanonical Wnt-5A
in experimental models of COPD and in human COPD that
functionally impaired canonical Wnt signal-driven alveolar
epithelial cell repair [239]. Overall, these findings suggest that
alterations in Wnt signalling may contribute to abnormal
repair and remodelling in COPD. As already highlighted, a
reduced expression of the epithelial pIgR has also been
reported in COPD that impairs the transepithelial transport
of secretory IgA [132, 240, 241]. Interestingly, a recent study
shows that pIgR-deficient mice develop COPD-like airway
and parenchymal remodelling, resulting from persistent
activation of inflammatory signalling by an altered lung
microbiome, thus suggesting that S-IgA deficiency may
play a role in small airway remodelling and disease pro-
gression in COPD [242] These findings are consistent with
the results of previous studies showing that reduced pIgR
expression in COPD epithelium correlates with the sever-
ity of airflow obstruction in this disease [241].
The dedifferentiation of the COPD epithelium through
aberrant regenerating mechanisms is responsible for an
altered physical, chemical, and immune response to inhaled
particles and microbes. Furthermore, epithelial cell activation
by cigarette smoke and other inhaled irritants in COPD
induces the release of inflammatory mediators, further
enhancing chronic airway inflammation. All these events
can increase airway epithelial damage and promote an excess
of extracellular matrix deposition and airway fibrosis, driving
disease progression in COPD [158]. Restoration of the epi-
thelial integrity by targeting signalling pathways involved in
aberrant repair and remodelling is promising but will need
further research [243, 244].
6. Conclusions and Therapeutic Perspectives
Cystic fibrosis is a genetic disease caused by mutations in the
CFTR gene, whereas COPD is mainly caused by environ-
mental factors—mostly cigarette smoking—on a genetically
susceptible background [1–4]. Although the etiology and
pathophysiology of these diseases are different, they share
key phenotypical features such as chronic neutrophilic
inflammation, progressive airflow obstruction, and recurrent
infectious exacerbations, suggesting the possibility of com-
mon mechanisms. In particular, COPD patients with the
chronic bronchitis phenotype exhibit pathologic and clinical
features similar to CF, including goblet cell hyperplasia,
mucin hyperexpression, mucus accumulation, and hyperse-
cretion that contribute to bacterial infection and subsequent
inflammatory responses, and have been associated with lung
function decline in COPD patients. Growing evidence
suggests that cigarette smoking induces an acquired CFTR
dysfunction in patients with COPD, reducing the expression
and/or function of the protein, and that this CFTR dysfunc-
tion is involved in most of the pathogenetic pathways
common to both COPD and CF.
Airway epithelial cells are among the first sites of
contact for pathogens and other noxious environmental
irritants and play a critical role in maintaining normal air-
way functions and the homeostasis of the airway milieu.
Relevant molecular and morphologic changes occur in the
airway epithelium in both CF and COPD, similar in some
aspects, and a growing body of evidence suggests that airway
epithelial dysfunction is involved in disease initiation and
progression in both diseases. Structural and functional
abnormalities in both airway and alveolar epithelium have a
relevant impact on alteration of host defences, immune/
inflammatory responses, and the repair processes, leading
to progressive lung damage and facilitating chronic and
recurrent airway infections in both CF and COPD.
An increasing number of studies show that CFTR dys-
function affects several physiological processes relevant to
airway epithelial cell functions, including chloride and bicar-
bonate transport, mucin secretion and MCC, host defences,
and inflammatory/immune responses. Thus, CFTR dysfunc-
tion represents a potential target for the development of
novel therapeutic approaches. An improved understanding
of the common mechanisms affected by CFTR dysfunction
in CF and COPD and the relevance of CFTR dysfunction in
the different COPD phenotypes would provide new insights
into disease pathogenesis and will be important for develop-
ing novel therapeutic strategies relevant to both diseases.
Recently, innovative and specific therapies targeting the
CFTR defect have been developed; in the context of the
increasing evidence about the role of CFTR dysfunction in
COPD, the possibility that therapies designed to correct the
CFTR dysfunction may benefit not only CF patients but also
patients with COPD is attractive and need further studies.
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